Is it possible for fit patients with chronic lymphocytic leukemia and a good prognosis to skip immunochemotherapy in favor of ibrutinib?
-
EHA 2020 – Fixed-duration ibrutinib in previously untreated CLL might spare immunotherapy for some -
EHA 2020 – ALL: chemotherapy conditioning before stem cell transplantation falls short Randomized global FORUM trial was stopped because of futility.
-
EHA 2020 – At second look, improvements seen for elderly patients with acute myeloid leukemia in Denmark After adjusting for age, positive trends become apparent in the survival of elderly Danish AML patients between the years 2000 and 2016.
-
EHA 2020 – Phase 3 trial follow-up confirms venetoclax-obinutuzumab in patients with previously untreated CLL A more efficient regimen may be in sight for “typical” patients with newly diagnosed chronic lymphocytic leukemia.
-
EHA 2020 – Retinoic acid improves survival in elderly patients with acute myeloid leukemia Independent research from Freiburg University (Germany) shows significant benefits of add-on all-trans retinoic acid for frail patients with AML.
-
EHA 2020 – Combination of venetoclax and navitoclax explored in pretreated patients with ALL A phase 1 study with heavily pretreated patients with relapsed or refractory ALL reports promising response rates for the combination of 2 BCL-2-inhibitors.
-
UK TARGET CML study finds little evidence that cardiovascular risk factors are considered during TKI management.
-
Secondary ALL: OS is worse than in de novo disease across all age groups Survival in ALL worsens with increasing age.
-
CML: a switch from branded to generic imatinib can retain benefits but save costs A single-center experience from the UK.
-
ALL: add-on rituximab shows no survival benefit in phase 3 Postinduction, MAallaSCT improves survival with rituximab.
-
Acalabrutinib improves survival in treatment-naive chronic lymphocytic leukaemia Results of the global, randomised, controlled, phase 3 ELEVATE TN trial.
-
EMA okays approvals for 3 oncology drugs Therapies for AML, MDS, and prostate cancer.
-
A report from the UK Childhood Cancer Study.
-
CLL: experts discuss workup and treatment strategies Key highlights from an interview.